1173019-29-8
1173019-29-8
Chemical Structure
Probucol-13C3
- CAS No.: 1173019-29-8
- Formula:C2813C3H48O2S2
- Molecular Weight:519.82
IUPAC Name: 4,4'-((propane-2,2-diyl-13C3)bis(sulfanediyl))bis(2,6-di-tert-butylphenol)
InChIKey: FYPMFJGVHOHGLL-DGVNISHSSA-N
SMILES: [13CH3][13C](SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1)(SC2=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C2)[13CH3]
Biological Activity: Probucol-13C3 is the 13C-labeled Probucol. Probucol (DH-581) is an anti-hyperlipidemic agent by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Probucol-13C3 | Probucol-13C3 is the 13C-labeled Probucol. Probucol (DH-581) is an anti-hyperlipidemic agent by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Probucol (Standard) | 99.86% | Probucol (Standard) is the analytical standard of Probucol. This product is intended for research and analytical applications. Probucol (DH-581) is an anti-hyperlipidemic agent by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Probucol-d6 | Probucol-d6 is deuterium labeled Probucol. Probucol (DH-581) is an anti-hyperlipidemic agent by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Probucol | 99.85% | Probucol (DH-581) is an anti-hyperlipidemic agent. Probucol activates glutathione peroxidase. Probucol promotes low density lipoprotein (LDL) catabolism, inhibits ABCA1-dependent cholesterol efflux, and decreases HDL-C levels. Probucol also has anti-inflammatory, antioxidant and neuroprotective properties. Probucol can be used for researches on bone, cardiovascular, cancer, neurological, and metabolism-related diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
